Gritstone bio Past Earnings Performance
Past criteria checks 0/6
Gritstone bio's earnings have been declining at an average annual rate of -11.2%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 10.8% per year.
Key information
-11.2%
Earnings growth rate
23.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 10.8% |
Return on equity | -599.5% |
Net Margin | -910.6% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
We Think Some Shareholders May Hesitate To Increase Gritstone bio, Inc.'s (NASDAQ:GRTS) CEO Compensation
Jun 11Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Apr 07Gritstone bio, Inc. (NASDAQ:GRTS) Analysts Just Slashed This Year's Revenue Estimates By 40%
Aug 14Gritstone bio: Early Data For SLATE Candidate Sets Up 2023 Catalyst
Sep 26Gritstone reaches six-month high on publication of data for cancer vaccine
Aug 16Gritstone bio announces $80M credit facility
Jul 21Is Gritstone bio (NASDAQ:GRTS) In A Good Position To Invest In Growth?
Jul 07Gritstone bio: Potential To Advance Colorectal Cancer Treatment
Jul 05Gritstone bio: Investing In A Premium mRNA Technology At A Discounted Valuation
Jun 14Some Analysts Just Cut Their Gritstone bio, Inc. (NASDAQ:GRTS) Estimates
Mar 17We're Not Very Worried About Gritstone bio's (NASDAQ:GRTS) Cash Burn Rate
Mar 05Gritstone: Why The Stock Fell On Positive Data
Jan 18Gritstone bio (NASDAQ:GRTS) Is In A Strong Position To Grow Its Business
Nov 23Gritstone Poised To Dominate mRNA Market
Nov 08Revenue & Expenses Breakdown
How Gritstone bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 15 | -133 | 32 | 0 |
31 Mar 24 | 16 | -145 | 31 | 0 |
31 Dec 23 | 16 | -138 | 29 | 0 |
30 Sep 23 | 10 | -139 | 28 | 0 |
30 Jun 23 | 12 | -130 | 27 | 0 |
31 Mar 23 | 15 | -125 | 28 | 0 |
31 Dec 22 | 20 | -120 | 29 | 0 |
30 Sep 22 | 19 | -118 | 29 | 0 |
30 Jun 22 | 18 | -116 | 29 | 0 |
31 Mar 22 | 16 | -112 | 27 | 0 |
31 Dec 21 | 48 | -75 | 26 | 0 |
30 Sep 21 | 46 | -72 | 25 | 0 |
30 Jun 21 | 45 | -70 | 24 | 0 |
31 Mar 21 | 42 | -71 | 23 | 0 |
31 Dec 20 | 4 | -105 | 21 | 0 |
30 Sep 20 | 4 | -106 | 21 | 0 |
30 Jun 20 | 4 | -107 | 21 | 0 |
31 Mar 20 | 4 | -103 | 20 | 0 |
31 Dec 19 | 4 | -94 | 19 | 0 |
30 Sep 19 | 5 | -84 | 18 | 0 |
30 Jun 19 | 4 | -75 | 16 | 0 |
31 Mar 19 | 3 | -69 | 14 | 0 |
31 Dec 18 | 1 | -65 | 12 | 0 |
30 Sep 18 | 0 | -65 | 10 | 0 |
30 Jun 18 | 0 | -56 | 8 | 0 |
31 Mar 18 | 0 | -47 | 7 | 0 |
31 Dec 17 | 0 | -41 | 6 | 0 |
Quality Earnings: GRTS is currently unprofitable.
Growing Profit Margin: GRTS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GRTS is unprofitable, and losses have increased over the past 5 years at a rate of 11.2% per year.
Accelerating Growth: Unable to compare GRTS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GRTS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: GRTS has a negative Return on Equity (-599.54%), as it is currently unprofitable.